MacroGenics Inc. (NASDAQ: MGNX) is closing in on the finish line to earn regulatory approval for its first product, a breast cancer therapy candidate. The Rockville biotech has submitted its Biologics License Application to the Food and Drug Administration for margetuximab, which targets “HER2” — a gene that can fuel cancer cell growth. FDA approval would give MacroGenics the final go-ahead to commercialize the product and treat patients with metastatic HER2-positive breast cancer along with…
from https://www.bizjournals.com/baltimore/news/2019/12/26/maryland-biotech-seeks-fda-approval-for-breast.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/189880012542
No comments:
Post a Comment